Exchange & Returns Information
Review Details
(0)
| Generic For | ORLISSA |
|---|---|
| Active Ingredient | ELAGOLIX |
| Strength | 200MG |
| Manufacturer | ALEMBIC PHARMA |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 10 TABLETS | $ 1.68 | $ 16.83 |
$ 14.31
Apply ZARVY26 (-15%)
You save $ 2.52
|
||
| 2 BOXES - 20 TABLETS | $ 1.64 |
3% $ 33.66
$ 32.74
|
$ 27.83
Apply ZARVY26 (-15%)
You save $ 4.91
|
||
| ★ Best Value 3 BOXES - 30 TABLETS | $ 1.56 |
7% $ 50.49
$ 46.89
|
$ 39.86
Apply ZARVY26 (-15%)
You save $ 7.03
|
Reference information will be available soon.
Unigolix 200 Tablet contains Elagolix 200 mg, a high-dose GnRH receptor antagonist designed for the short-term management of severe endometriosis-associated pain. By directly blocking GnRH receptors in the pituitary gland, it rapidly suppresses LH and FSH secretion, leading to a sharp, reversible reduction in estrogen levels. At a 200 mg twice-daily regimen, it induces a near-menopausal hormonal state, providing aggressive relief from dysmenorrhea, dyspareunia, and pelvic pain. To offset hypoestrogenic side effects such as bone mineral density loss and vasomotor symptoms, therapy is typically combined with add-back treatment (estradiol + norethindrone). As an oral alternative to injectable GnRH agonists, Unigolix offers effective pain management with convenient dosing flexibility.
HORMONES & MENOPAUSAL SYMPTOMS > Endometriosis
Indicated for the treatment of moderate to severe pelvic pain, menstrual cramping, and dyspareunia due to endometriosis, particularly in patients requiring deeper estrogen suppression.
AntiCancer Drugs > Uterine Fibroid
Used off-label for managing heavy menstrual bleeding and pain associated with uterine fibroids; often administered as part of non-surgical treatment strategies or pre-surgical preparation.
GnRH receptor antagonism: Elagolix 200 mg competitively binds to GnRH receptors in the anterior pituitary, suppressing LH and FSH secretion and sharply reducing ovarian estrogen production.
Rapid onset of action: Unlike GnRH agonists, it does not cause an initial hormonal flare and begins acting within hours of administration.
Hypoestrogenic environment: At higher doses, induces a near-menopausal state, effectively controlling estrogen-dependent conditions such as endometriosis and uterine fibroids.
Symptom relief: Provides strong efficacy in reducing pelvic pain, dysmenorrhea, dyspareunia, and heavy bleeding.
Add-back therapy relevance: Due to risks of vasomotor symptoms, mood changes, and bone mineral density loss, concurrent low-dose estradiol + norethindrone (add-back therapy) is recommended for longer treatment courses.
Usual Adult Dose (Endometriosis)
200 mg orally twice daily for up to 6 months (commonly prescribed with add-back therapy)
Administration Guidelines
Confirm absence of pregnancy before initiation, or begin within 7 days of menstrual onset
Limit therapy duration due to risk of bone mineral density reduction
Add-back therapy (low-dose estradiol + norethindrone) is recommended to reduce vasomotor and skeletal side effects while maintaining efficacy
Avoid use beyond 6 months in women with moderate hepatic impairment or those at risk of osteoporosis
This medication is not a contraceptive; advise patients to use non-hormonal contraception during treatment
General Notes
Monitor bone density and liver function with prolonged therapy
Missed Dose: Take as soon as remembered; if close to next dose, skip and continue as scheduled. Do not double dose
Discontinuation: Symptoms typically recur after cessation; ongoing management plan should be discussed with physician
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
